Introduction
Pregabalin is a new ligand for the alpha-2-delta subunit associated with voltage-gated calcium channels. Pregabalin has been shown to be effective against seizures in a wide range of animal models, has a linear pharmacokinetic profile, lack of protein binding, lack of hepatic metabolism, and renal excretion. No drug-drug interactions have been observed during clinical development. 1 Data from three pivotal studies [2] [3] [4] indicate that PGB is highly effective as adjunctive therapy in the treatment of patients with partial seizures, with or without secondary generalization. The improvement rates in these studies including highly refractory patients ranged between 17.4% and 39.5%, with a good profile of safety and tolerability. 5 Most frequently reported adverse events have been dizziness, ataxia, weight gain, asthenia and somnolence. We report our experience with PGB when used in every Seizure (2007) day clinical practice as add-on therapy in patients with refractory epilepsy attending two Epilepsy Units in tertiary hospitals.
Patients and methods
We retrospectively identified epileptic patients with persistent partial seizures in spite of treatment with one, two or three antiepileptic drugs (AEDs), who received PGB as add-on treatment and were followed up for at least 1 year. The patients attended the Epilepsy Clinics of two tertiary hospitals, Hospital Clínic (Barcelona, Spain) and Hospital Josep Trueta (Girona, Spain). We reviewed their charts and analyzed type of epilepsy, number of concomitant AEDs, seizure frequency before and after 6 and 12 months of PGB, treatment emergent adverse effects and retention rate at 12 months. The analysis was performed on an intent-to-treat basis.
Results
A total of 101 patients (56 women and 45 men) received PGB as add-on treatment for refractory partial epilepsy and have been followed up for at least 1 year. Mean age was 40 years (16-64); mean time from seizure onset was 22 years (7-53), mean number of concomitant AEDs was 2.8. Eight patients had history of recent status epilepticus or clusters of seizures which prevented them from participating in clinical trials.
All patients had focal epilepsy. Most patients had temporal lobe epilepsy (43 patients), followed by frontal lobe epilepsy (29 patients), unlocalized focal epilepsy (23 patients), parieto-occipital epilepsy (4 patients) and multifocal epilepsy (2 patients). Seizures were highly refractory, with a median number of seizures per month of 16 (3-240).
Mean PGB dose reached was 412.5 mg (range 150-600). The titration scheme was similar in both Epilepsy Units, with PGB started at a dose of 75 mg a day, and then increased weekly by 75 mg until maximum tolerated dose or 600 mg.
Responder rate (percentage of patients with 50% seizure reduction) at 6 and 12 months follow-up was 52% and 39.6%, respectively. Four patients reported similar number of seizures but less severity (shorter seizures or absence of generalized tonic clonic convulsions). Seizure freedom for at least 6 and 12 months has been achieved by 12 (11.8%) and 6 (5.9%) patients, respectively. Increase in seizure frequency, temporally related to the drug, was seen in four patients (3.9%). PGB was generally well tolerated. Sixty per cent of patients reported at least one adverse effect, being weight gain 10% body weight the most frequent, seen in 26 patients (25.7%). Weight gain was seen in 18/56 women and 8/45 men. Dizziness/ataxia was seen in 20 patients (19.8%). Dizziness/ataxia was especially severe when PGB was added to regimens containing PHT, CBZ or OXC. Dizziness/ataxia usually resolved after lowering the dose of concomitant AEDs (by 30-50%), with no need to lower the total daily dose of PGB.
Ten patients (9.9%) displayed lower limb oedema not accompanied by ionic or other metabolic disturbances, and four patients (3.9%) had dose-dependent blurred vision. There were few cognitive side effects, with only three patients reporting psychomotor slowing. Unusual side effects included enuresis (one patient) and impotence (one patient). Adverse effects were generally mild to moderate in severity. Only four patients had severe adverse effects (weight gain leading to worse control of concomitant diabetes mellitus, severe ataxia in one patient who had concomitant treatment with OXC which improved when lowering OXC dose, severe increase in seizure frequency (100%) and suicide attempt in one patient with a previously known depression, which was not considered to be drug related).
At 12 months, 61 patients continued taking PGB (retention rate at 1 year: 60.4%) (Fig. 1) . Forty patients (39.6%) discontinued PGB, because of inefficacy (16 patients, 15.8%), adverse effects (15 patients, 14.8%) or both (9 patients, 8.9%).
Discussion
Our study confirms, under every day clinical practice conditions, previous data provided by controlled studies about efficacy and tolerability of PGB when used as add-on therapy in patients with refractory partial seizures.
The responder rates observed at 6 and 12 months (52% and 39.6%, respectively) observed in our population of highly refractory epileptic patients is encouraging, when considering that these patients had a very high number of monthly seizures and were treated with a mean number of 2.8 other AEDs. In a recent study, 6 the responder rate was 31.3% for a PGB flexible dose regimen which tried to reproduce routine clinical practice. It does not seem that our strategy of decreasing dose of certain concomitant AEDs decreases overall treatment efficacy; it improves tolerability and, in our experience, it is necessary in many patients to reach medium or high PGB doses.
A particularly important fact in clinical practice when treating refractory patients is the number of patients who become seizure free with a new AED. In fact, this is the goal for every patient and also for the prescribing physician, with seizure freedom being the most significant factor associated with quality of life in epilepsy. 7 According to several authors, at least 6-month seizure free periods should be provided for a meaningful estimation of long term efficacy of AEDs. 8, 9 In our series, seizure freedom for at least 6 and 12 months was achieved by 12 (11.8%) and 6 (5.9%) patients, respectively, which is similar to the percentages attained with other new AEDs in patients with intractable epilepsy. 10 Retention rate at 1 year is also similar to previously reported figures for LEV or TPM in similar populations. 11, 12 Retention rate may be influenced by factors independent from efficacy. In the absence of significant adverse reactions, patients may continue on PGB even if seizure response was not optimum, in the lack of a new alternative (ZNS was not available in Spanish market until March 2006).
Adverse effects are always of concern in a population of refractory patients, as polytherapy increases significantly the risk of toxicity. In our series, most side effects were mild to moderate in intensity. Discontinuation rate because of adverse effects was lower than in controlled studies, as expected in daily clinical practice, but similar to the flexible dose study. 6 Experience acquired with other AEDs led us to use a slower than recommended titration rate. We feel that a starting dose of 75 mg a day, with weekly increments of 75 mg, is adequate and may be better tolerated, specially when treating patients who receive two or more concomitant AEDs.
Weight gain was frequently seen. This adverse effect has also been observed in controlled studies. It may be appropriate to recommend a low calorie diet in patients who are prescribed PGB and to control weight in every visit. Regarding lower limb oedema, routine laboratory tests are normal in these patients, and the oedema usually improves when lowering PGB dose. Cognitive side effects, which have a very negative impact in social and laboral life of refractory epileptic patients, were seen in few patients.
Limitations of our study include its retrospective nature and the fact that the control data are historical rather than contemporary. However, we believe it can provide useful information to the clinicians given the size of the population studied and the pattern of use of the drug, reflecting conditions of actual clinical practice rather than the somewhat artificial situation of a clinical trial.
In summary, PGB seems an effective and well tolerated AED when used as add-on treatment in patients with refractory partial epilepsy. When used in every day clinical practice in highly refractory patients, it may decrease seizure frequency by 50% or more in up to 39% of patients at 1 year. Low discontinuation rate due to adverse events was seen, which is likely the result of slow titration, lowering of concomitant AEDs and individual dose adjustment.
